PERES KORIE: Open Payments
NPI 1578218400 · OWINGS MILLS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$552 in 25 payments from 14 companies in 2025. Trend: 2023 $66 · 2024 $22 · 2025 $552
Food & beverage: $552
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $201 |
| Dynavax Technologies Corporation | 2 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Exact Sciences Corporation | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
Products named: Ozempic, Heplisav-B, Kerendia, REXULTI, MOUNJARO, Wegovy, REZDIFFRA, XIFAXAN.
Industry payments across MD — which companies pay providers there.
